StockData
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

BOSTON SCIENTIFIC CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)

Close on Oct 19, 2026

Market cap
$66.44B
P/E (TTM)
18.2
Dividend yield
–

Earnings

Next report expected Oct 21, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026Before market open$5.44B$0.61$0.86
Q1 FY2026
Ended Mar 31, 2026
Apr 22, 2026Before market open$5.20B$0.90$0.80
Q4 FY2025
Ended Dec 31, 2025
Feb 4, 2026Before market open$5.29B$0.45$0.80
Q3 FY2025
Ended Sep 30, 2025
Oct 22, 2025Before market open$5.07B$0.51$0.75
Q2 FY2025
Ended Jun 30, 2025
Jul 23, 2025Before market open$5.06B$0.53$0.75
Q1 FY2025
Ended Mar 31, 2025
Apr 23, 2025Before market open$4.66B$0.45$0.75
Q4 FY2024
Ended Dec 31, 2024
Feb 5, 2025Before market open$4.56B$0.38$0.70
Q3 FY2024
Ended Sep 30, 2024
Oct 23, 2024Before market open$4.21B$0.32$0.63
Q2 FY2024
Ended Jun 30, 2024
Jul 24, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
Apr 24, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Jan 31, 2024Before market open–––

Company guidance

Outlook given with results on Jul 29, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
adjusted EPSnon-GAAPfull year 2026$3.28 to $3.32Lowered
adjusted EPSnon-GAAPthird quarter of 2026$0.80 to $0.82New
net sales growthGAAPfull year 20265.5% to 6.5% growthLowered
organic net sales guidancenon-GAAPfull year 20265% to 6% growthLowered
net sales growthGAAPthird quarter of 20263% to 5% growthNew
organic net sales guidancenon-GAAPthird quarter of 20263% to 5% growthNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Boston Scientific filed with the SEC